Johnson & Johnson’s targeted therapeutic combination, Tecvayli-Darzalex Faspro, performed better than investigator’s choice standard of care in a Phase III trial recruiting patients with R/R multiple ...

dashClinical provides instant payments that enhance trial completion and subject retention. Credit: PeopleImages/Shutterstock.com. Dash Solutions has introduced ...

The company has announced positive data from the ACHIEVE-2 and ACHIEVE-5 trials, with both meeting all their primary and key ...

Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

While MFN will see US drug prices reduced to match other countries, by them increasing elsewhere and using alternative models, it is unlikely that R&D will be heavily impacted. Image credit: ...

OS Therapies’ cancer vaccine, OST-HER2, has offered improvements to overall survival (OS) in a Phase II trial in METS osteosarcoma. Image credit: sweet_tomato via ShutterStock.com. OS Therapies’ ...

Sanofi acquired commercialisation rights for the radiopharmaceutical AlphaMedix from Orana Med in September 2024.

The antibody is currently under development for hereditary angioedema treatment. Credit: Akimov Igor/Shutterstock.com. Astria Therapeutics has commenced the Phase III ORBIT-EXPANSE long-term study ...

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...